Nifty
:
11186.75
Sensex
:
37902.99
-63.80 (-0.57%)
-131.15 (-0.34%)
Nifty
Sensex
:
:
11186.75
37902.99
-63.80 (-0.57%)
-131.15 (-0.34%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
71/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
503.65
21-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  523.80
  •  528.25
  •  499.00
  •  523.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  9983045
  •  51312.48
  •  564.75
  •  312.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 120,842.51
  • 167.41
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 122,669.84
  • 0.79%
  • 2.82

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.69%
  • 3.51%
  • 7.45%
  • FII
  • DII
  • Others
  • 12.7%
  • 19.06%
  • 2.59%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 19.08
  • 3.16
  • 7.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.63
  • -3.09
  • 4.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.59
  • -3.62
  • 21.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 36.13
  • 33.86
  • 37.02

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.16
  • 3.82
  • 2.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.70
  • 16.90
  • 15.89

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
7,585.25
8,374.36
-9.42%
8,184.94
7,163.92
14.25%
8,154.85
7,740.19
5.36%
8,123.35
6,937.63
17.09%
Expenses
5,820.90
6,446.13
-9.70%
6,821.93
6,147.13
10.98%
6,395.25
5,814.48
9.99%
6,333.61
5,406.42
17.15%
EBITDA
1,764.35
1,928.23
-8.50%
1,363.01
1,016.79
34.05%
1,759.60
1,925.71
-8.63%
1,789.74
1,531.21
16.88%
EBIDTM
3.55%
23.03%
14.01%
14.19%
21.58%
24.88%
22.03%
22.07%
Other Income
232.95
280.40
-16.92%
102.23
281.53
-63.69%
201.68
420.24
-52.01%
200.85
351.15
-42.80%
Interest
51.95
104.06
-50.08%
51.78
150.03
-65.49%
62.96
144.79
-56.52%
83.93
129.53
-35.20%
Depreciation
495.92
457.13
8.49%
575.38
454.05
26.72%
546.99
471.05
16.12%
473.28
426.51
10.97%
PBT
15.41
1,647.44
-99.06%
577.44
694.24
-16.82%
1,351.33
1,730.11
-21.89%
1,433.38
111.94
1,180.49%
Tax
1.10
146.06
-99.25%
83.09
-28.81
-
327.62
270.92
20.93%
266.03
269.69
-1.36%
PAT
14.31
1,501.38
-99.05%
494.35
723.05
-31.63%
1,023.71
1,459.19
-29.84%
1,167.35
-157.75
-
PATM
37.11%
17.93%
7.11%
10.09%
12.55%
18.85%
14.37%
-2.27%
EPS
0.06
6.26
-99.04%
2.06
3.01
-31.56%
4.27
6.08
-29.77%
4.87
-0.66
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
32,048.39
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
5,727.90
Net Sales Growth
6.06%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
40.01%
 
Cost Of Goods Sold
9,134.21
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
1,460.40
Gross Profit
22,914.18
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
4,267.50
GP Margin
71.50%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
74.50%
Total Expenditure
25,371.69
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
3,785.07
Power & Fuel Cost
-
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
145.65
96.78
% Of Sales
-
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
1.69%
Employee Cost
-
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
818.95
% Of Sales
-
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
14.30%
Manufacturing Exp.
-
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
338.40
% Of Sales
-
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
5.91%
General & Admin Exp.
-
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
480.66
% Of Sales
-
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
8.39%
Selling & Distn. Exp.
-
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
372.14
% Of Sales
-
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
6.50%
Miscellaneous Exp.
-
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
464.95
246.76
372.14
% Of Sales
-
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
3.80%
EBITDA
6,676.70
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
1,942.83
EBITDA Margin
20.83%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
33.92%
Other Income
737.71
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
375.08
Interest
250.62
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
73.88
Depreciation
2,091.57
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
204.85
PBT
3,377.56
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
2,039.18
Tax
677.84
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
313.19
128.58
Tax Rate
20.07%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
6.31%
PAT
2,699.72
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
1,819.29
PAT before Minority Interest
2,494.78
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
1,910.60
Minority Interest
-204.94
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
-91.31
PAT Margin
8.42%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
31.76%
PAT Growth
-23.43%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
12.48%
46.09%
 
EPS
11.25
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46
11.08
7.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
9,483.32
Share Capital
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
103.56
103.56
Total Reserves
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
9,379.76
Non-Current Liabilities
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
-188.27
Secured Loans
257.49
109.47
217.69
185.59
7.73
40.69
43.76
41.90
49.65
4.38
Unsecured Loans
1,771.43
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
152.90
Long Term Provisions
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
13.00
Current Liabilities
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
1,730.88
Trade Payables
4,093.73
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
645.38
Other Current Liabilities
1,891.11
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
362.42
Short Term Borrowings
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
207.78
Short Term Provisions
4,172.21
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
515.30
Total Liabilities
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08
Net Block
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
3,293.35
Gross Block
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
5,319.27
Accumulated Depreciation
12,269.06
9,849.21
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
2,025.92
Non Current Assets
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
4,279.84
Capital Work in Progress
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
235.46
Non Current Investment
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
346.01
Long Term Loans & Adv.
4,060.77
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
377.27
Other Non Current Assets
49.24
21.96
50.21
682.18
953.34
103.94
34.20
42.90
18.71
27.75
Current Assets
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
7,593.05
Current Investments
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
1,883.75
Inventories
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
1,489.48
Sundry Debtors
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
1,104.87
Cash & Bank
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
2,204.63
Other Current Assets
2,973.02
997.09
891.31
718.25
2,847.64
5,026.16
3,774.42
1,149.11
1,136.55
910.32
Short Term Loans & Adv.
1,431.54
2,075.60
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
784.37
Net Current Assets
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
5,862.17
Total Assets
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
11,873.08

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
2,283.10
PBT
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
2,035.95
Adjustment
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
-171.18
Changes in Working Capital
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
487.65
Cash after chg. in Working capital
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
2,352.42
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
-69.32
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
-1,847.71
Net Fixed Assets
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
-212.50
Net Investments
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
450.27
Others
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
-2,085.48
Cash from Financing Activity
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
-804.19
Net Cash Inflow / Outflow
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
-368.80
Opening Cash & Equivalents
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
633.87
Closing Cash & Equivalent
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67
810.49

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
59.08
45.79
ROA
6.58%
5.17%
4.24%
14.08%
11.39%
14.60%
16.21%
19.61%
22.00%
18.43%
ROE
9.66%
8.05%
6.85%
22.51%
19.32%
24.89%
23.15%
25.53%
28.02%
22.07%
ROCE
10.07%
8.68%
8.40%
21.48%
18.64%
25.06%
25.46%
31.39%
30.13%
23.60%
Fixed Asset Turnover
1.78
1.92
1.99
1.35
1.34
1.79
1.70
1.51
1.38
1.44
Receivable days
56.22
54.10
53.53
80.78
76.12
48.20
51.72
71.46
71.49
71.57
Inventory Days
48.40
47.84
48.88
76.61
77.46
57.99
63.92
74.22
80.31
80.48
Payable days
63.32
77.81
90.19
77.57
75.24
52.05
56.33
65.15
64.51
51.06
Cash Conversion Cycle
41.30
24.13
12.23
79.82
78.34
54.14
59.31
80.53
87.29
100.98
Total Debt/Equity
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
0.04
Interest Cover
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13
120.02
28.60

Annual Reports:

FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012
FY 2011

News Update:


  • Sun Pharma launches FluGuard in India at Rs 35 per tablet
    4th Aug 2020, 16:20 PM

    The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country

    Read More
  • Sun Pharma Inds. - Quarterly Results
    31st Jul 2020, 14:49 PM

    Read More
  • Sun Pharma's arm to acquire outstanding shares of Aquinox Pharmaceuticals
    29th Jul 2020, 10:23 AM

    Cash consideration of $8.2 million would be paid for acquisition of all shares

    Read More
  • Sun Pharma's arm resolves all cases with US DOJ
    24th Jul 2020, 14:38 PM

    The US Department of Justice had launched investigations against the company over generic drug pricing

    Read More
  • Sun Pharma aims to gain market share in all verticals amid coronavirus pandemic
    20th Jul 2020, 09:09 AM

    The company also looks to focus on cash preservation and finding a way to reduce the overall debt for the company

    Read More
  • Sun Pharma launches ‘Thank you Doctor’ campaign
    11th Jul 2020, 11:26 AM

    The company has launched campaign to express gratitude towards doctors for their sacrifices and selfless service

    Read More
  • Sun Pharma’s arm gets Japan MHLW approval for ILUMYA for treatment of Plaque Psoriasis
    29th Jun 2020, 12:35 PM

    Japan has approximately 430,000 people currently suffering from psoriasis

    Read More
  • Sun Pharma’s arm inks pact with Hikma Pharmaceuticals for ILUMYA
    15th Jun 2020, 13:18 PM

    ILUMYA is used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.